- Home
- ANGO vs KURA Comparison
ANGO vs KURA Comparison
Compare ANGO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- KURA
- Stock Information
- Founded
- ANGO 1988
- KURA 2014
- Country
- ANGO United States
- KURA United States
- Employees
- ANGO N/A
- KURA N/A
- Industry
- ANGO Medical/Dental Instruments
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANGO Health Care
- KURA Health Care
- Exchange
- ANGO Nasdaq
- KURA Nasdaq
- Market Cap
- ANGO 439.5M
- KURA 492.9M
- IPO Year
- ANGO 2004
- KURA N/A
- Fundamental
- Price
- ANGO $9.11
- KURA $5.76
- Analyst Decision
- ANGO Strong Buy
- KURA Strong Buy
- Analyst Count
- ANGO 2
- KURA 11
- Target Price
- ANGO $14.00
- KURA $23.89
- AVG Volume (30 Days)
- ANGO 330.9K
- KURA 1.5M
- Earning Date
- ANGO 04-02-2025
- KURA 05-01-2025
- Dividend Yield
- ANGO N/A
- KURA N/A
- EPS Growth
- ANGO N/A
- KURA N/A
- EPS
- ANGO N/A
- KURA N/A
- Revenue
- ANGO $283,320,000.00
- KURA $67,991,000.00
- Revenue This Year
- ANGO N/A
- KURA $44.32
- Revenue Next Year
- ANGO $6.35
- KURA $173.73
- P/E Ratio
- ANGO N/A
- KURA N/A
- Revenue Growth
- ANGO N/A
- KURA N/A
- 52 Week Low
- ANGO $5.47
- KURA $5.41
- 52 Week High
- ANGO $13.50
- KURA $23.48
- Technical
- Relative Strength Index (RSI)
- ANGO 46.41
- KURA 39.73
- Support Level
- ANGO $8.55
- KURA $5.48
- Resistance Level
- ANGO $9.68
- KURA $6.76
- Average True Range (ATR)
- ANGO 0.36
- KURA 0.34
- MACD
- ANGO -0.02
- KURA -0.02
- Stochastic Oscillator
- ANGO 46.28
- KURA 21.88
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.